Publications (2010)
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Vergote IE, Pujade-Lauraine E,Pignata S, Kristensen GB, Ledermann JA, Casado A, Sehouli J, Mirza M, Fossati R, Marth C. Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee Ate GJ, du Bois A
Int Gynecol Cancer, 20: 476-478 (2010)
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al
Br J Cancer, 102(7): 1123-1128 (2010)
Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M
Br J Haematol. Apr;149(2):237-43. Epub 2010 Mar 1 (2010)
Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumors
Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Buscombe J, Grillo J, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T
Br J Cancer, doi:10.1038/sj.bjc.6605618 (2010)
